Abiomed, Inc.
ABMD · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11,146 | $11,280 | $15,079 | $16,345 |
| - Cash | $182 | $180 | $133 | $144 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $10,964 | $11,100 | $14,947 | $16,201 |
| Revenue | $266 | $277 | $270 | $261 |
| % Growth | -4.1% | 2.7% | 3.3% | – |
| Gross Profit | $217 | $225 | $218 | $214 |
| % Margin | 81.6% | 81% | 80.9% | 81.8% |
| EBITDA | $226 | $80 | $92 | $72 |
| % Margin | 85% | 28.9% | 34% | 27.4% |
| Net Income | $106 | $55 | $60 | $46 |
| % Margin | 39.9% | 19.7% | 22.4% | 17.5% |
| EPS Diluted | 2.32 | 1.19 | 1.31 | 1 |
| % Growth | 95% | -9.2% | 31% | – |
| Operating Cash Flow | $13 | $68 | $79 | $90 |
| Capital Expenditures | -$6 | -$7 | -$15 | -$6 |
| Free Cash Flow | $8 | $61 | $64 | $84 |